{"id":919187,"date":"2025-12-12T06:35:02","date_gmt":"2025-12-12T11:35:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/"},"modified":"2025-12-12T06:35:02","modified_gmt":"2025-12-12T11:35:02","slug":"clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/","title":{"rendered":"Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement"},"content":{"rendered":"
\n

Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that on December 10, 2025, the Company received a notification letter from Nasdaq stating that, based on the Company\u2019s Form 6-K filed on December 5, 2025, it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the \u201cMinimum Stockholders\u2019 Equity Rule\u201d), which requires listed companies to maintain stockholders\u2019 equity of at least $2,500,000.<\/p>\n

Nasdaq has informed the Company that it will continue to monitor the Company\u2019s compliance with the Minimum Stockholders\u2019 Equity Rule. If, at the time of the Company\u2019s next periodic report, the Company does not demonstrate compliance with this requirement, the Company may be subject to delisting.<\/p>\n

\n About\u00a0Clearmind\u00a0Medicine Inc.<\/b>\n <\/p>\n

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.<\/p>\n

The Company\u2019s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.<\/p>\n

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol \u201cCWY0.\u201d<\/p>\n

For further information, visit:\u00a0https:\/\/www.clearmindmedicine.com<\/a>\u00a0or contact:<\/p>\n

Investor Relations
invest@clearmindmedicine.com<\/a><\/p>\n

Telephone: (604) 260-1566
US:\u00a0CMND@crescendo-ir.com<\/a><\/p>\n

General Inquiries
Info@Clearmindmedicine.com<\/a>
www.Clearmindmedicine.com<\/a> \u00a0\u00a0<\/p>\n

\n Forward-Looking Statements:<\/b>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the Company\u2019s ability to maintain compliance Nasdaq Listing Rules. Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith.\u00a0However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is\u00a0made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission (\u201cSEC\u201d), including, but not limited to, the risks detailed in the Company\u2019s annual report on Form 20-F for the fiscal year ended October 31,\u00a02024\u00a0and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that on December 10, 2025, the Company received a notification letter from Nasdaq stating that, based on the Company\u2019s Form 6-K filed on December 5, 2025, it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the \u201cMinimum Stockholders\u2019 Equity Rule\u201d), which requires listed companies to maintain stockholders\u2019 equity of at least $2,500,000. Nasdaq has informed the Company that it will continue to monitor the Company\u2019s compliance with the Minimum Stockholders\u2019 Equity Rule. If, at the time of the Company\u2019s … <\/p>\n

Continue reading “Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919187","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nClearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that on December 10, 2025, the Company received a notification letter from Nasdaq stating that, based on the Company\u2019s Form 6-K filed on December 5, 2025, it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the \u201cMinimum Stockholders\u2019 Equity Rule\u201d), which requires listed companies to maintain stockholders\u2019 equity of at least $2,500,000. Nasdaq has informed the Company that it will continue to monitor the Company\u2019s compliance with the Minimum Stockholders\u2019 Equity Rule. If, at the time of the Company\u2019s … Continue reading "Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-12T11:35:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement\",\"datePublished\":\"2025-12-12T11:35:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/\"},\"wordCount\":633,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/\",\"name\":\"Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==\",\"datePublished\":\"2025-12-12T11:35:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/","og_locale":"en_US","og_type":"article","og_title":"Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Market Newsdesk","og_description":"Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that on December 10, 2025, the Company received a notification letter from Nasdaq stating that, based on the Company\u2019s Form 6-K filed on December 5, 2025, it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the \u201cMinimum Stockholders\u2019 Equity Rule\u201d), which requires listed companies to maintain stockholders\u2019 equity of at least $2,500,000. Nasdaq has informed the Company that it will continue to monitor the Company\u2019s compliance with the Minimum Stockholders\u2019 Equity Rule. If, at the time of the Company\u2019s … Continue reading \"Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-12T11:35:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement","datePublished":"2025-12-12T11:35:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/"},"wordCount":633,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/","name":"Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==","datePublished":"2025-12-12T11:35:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTMzMiM3MzE5MzQ1IzUwMDA4NjkzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-successfully-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919187"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919187\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}